Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer

NCT03091660 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT03091660
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03091660 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 24, 2017
Completion date
June 15, 2026
Enrollment
1,000 (actual)
Sites
174

Conditions

As the registry lists them; a condition with its own page is linked.

stage 0 bladder urothelial carcinoma, stage 0is bladder urothelial carcinoma, stage i bladder urothelial carcinoma